Macquarie Group
TGTX icon

Macquarie Group’s TG Therapeutics TGTX Stock Holding History

Macquarie Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,608
Closed -$60K – 2102
2022
Q3 		$60K Sell
3,608
-6,582
-65% -$43.2K ﹤0.01% 1909
2022
Q2 		$43K Buy
10,190
+5,152
+102% +$32.2K ﹤0.01% 2092
2022
Q1 		$48 Hold
5,038
– – ﹤0.01% 2155
2021
Q4 		$96K Buy
5,038
+878
+21% +$22.8K ﹤0.01% 1952
2021
Q3 		$138K Buy
4,160
+1,277
+44% +$39.5K ﹤0.01% 1876
2021
Q2 		$112K Hold
2,883
– – ﹤0.01% 1940
2021
Q1 		$139K Buy
2,883
+261
+10% +$12.5K ﹤0.01% 1816
2020
Q4 		$136K Hold
2,622
– – ﹤0.01% 1802
2020
Q3 		$70K Hold
2,622
– – ﹤0.01% 1871
2020
Q2 		$51K Buy
+2,622
New +$42.2K ﹤0.01% 1924
2019
Q1 		– Sell
-500
Closed -$2K – 2015
2018
Q4 		$2K Hold
500
– – ﹤0.01% 2200
2018
Q3 		$3K Sell
500
-67,101
-99% -$767K ﹤0.01% 2113
2018
Q2 		$889K Buy
67,601
+15,377
+29% +$211K ﹤0.01% 1214
2018
Q1 		$742K Buy
+52,224
New +$667K ﹤0.01% 1260

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Macquarie Group's TGTX Position: Q4 2022 in Review

Macquarie Group sold out of TG Therapeutics (TGTX) in Q4 2022, closing a stake of 3,608 shares — an estimated $60K sold.

Macquarie Group first reported a position in TGTX in Q1 2018 and held it in 14 quarters. The position peaked at $889K in Q2 2018. 198 funds tracked by Wall St. Rank hold TGTX as of Q4 2022.

  • Macquarie Group reported no remaining TG Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Macquarie Group sold 3,608 TG Therapeutics shares in Q4 2022, an estimated $60K.
  • Macquarie Group first reported a position in TG Therapeutics in Q1 2018 and held it in 14 quarters.
  • Macquarie Group's TG Therapeutics position peaked at $889K in Q2 2018.
  • 198 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.